Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 1.00 |
| ▸ | SQLE | Q14534 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | EBP | Q15125 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terbinafine SCHEMBL2028187 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1SQLE | |
| Terbinafine SCHEMBL2042785 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1SQLE | |
| Terbinafine SCHEMBL29353314 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1SQLE | |
| Terbinafine SCHEMBL31374681 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1SQLE | |
| Terbinafine SCHEMBL36794 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1SQLE | |
| Terbinafine SCHEMBL5279646 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1SQLE | |
| Terbinafine SCHEMBL37843 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1SQLE | |
| Terbinafine SCHEMBL36795 | 0.99 | CYP2D6 (0.97) | CYP2D6LMNASLC6A2SIGMAR1SQLE | |
| Terbinafine SCHEMBL3597456 | 0.99 | CYP2D6 (0.97) | CYP2D6LMNASLC6A2SIGMAR1SQLE | |
| Terbinafine SCHEMBL29871278 | 0.99 | CYP2D6 (0.97) | CYP2D6LMNASLC6A2SIGMAR1SQLE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3045161-B1 | Use of active mixtures of 1,2-hexanediol and 1,2-octanediol in cosmetic, pharmaceutical or dermatological emulsions | SYMRISE AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-20250188156-A1 | ANTIBODY COMPOSITIONS FOR DISRUPTING BIOFILMS | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL | 2025-06-12 | — | — | US | disclosed |
| US-20250146046-A1 | METHODS FOR DETERMINING ANTIBIOTIC SENSITIVITY | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2025-05-08 | — | — | US | disclosed |
| CN-119504987-A | Antibody compositions for disrupting biological membranes | 国家儿童医院研究所 | 2025-02-25 | — | — | CN | disclosed |
| CN-115073303-B | Preparation method of terbinafine hydrochloride Z-type isomer | 乐泰药业(兰西)有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-12209118-B2 | Antibody compositions for disrupting biofilms | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2025-01-28 | — | — | US | disclosed |
| CN-114401986-B | Antibody compositions for disrupting biological membranes | 国家儿童医院研究所 | 2024-11-08 | — | — | CN | disclosed |
| US-12116614-B2 | Methods for determining antibiotic sensitivity | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2024-10-15 | — | — | US | disclosed |
| US-20230414512-A1 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same | LABORATORY SKIN CARE, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230404871-A1 | PEROXIDE GEL COMPOSITIONS | CAO GROUP, INC. (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230061518-A1 | PEROXIDE GEL COMPOSITIONS | CAO GROUP, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| EP-2427178-B1 | DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME | LABORATORY SKIN CARE INC (US) | 2023-01-04 | — | — | EP | disclosed |
| US-11485730-B2 | Compositions and methods for the treatment of fungal infections | CELLIX BIO PRIVATE LIMITED (IN) | 2022-11-01 | — | — | US | disclosed |
| US-20220340551-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2022-10-27 | — | — | US | disclosed |
| CN-115073303-A | Preparation method of terbinafine hydrochloride Z-type isomer | 乐泰药业(兰西)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220275064-A1 | ANTIBODY COMPOSITIONS FOR DISRUPTING BIOFILMS | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL | 2022-09-01 | — | — | US | disclosed |
| US-20220233417-A1 | PEROXIDE GEL COMPOSITIONS | CAO GROUP, INC. | 2022-07-28 | — | — | US | disclosed |
| US-20220213073-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-07 | — | — | US | disclosed |
| EP-3997120-A2 | ANTIBODY COMPOSITIONS FOR DISRUPTING BIOFILMS | Research Institute at Nationwide Children's Hospital (US) | 2022-05-18 | — | — | EP | disclosed |
| US-11312707-B2 | Compositions and methods for the treatment of fungal infections | CELLIX BIO PRIVATE LIMITED (IN) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485730-B2 | Compositions and methods for the treatment of fungal infections | SI, CYP3A7, ERG28 | CYP2D6 14/4885LMNA 2173/4885SLC6A2 1255/4885 |
| US-11312707-B2 | Compositions and methods for the treatment of fungal infections | SI, CYP3A7, ERG28 | CYP2D6 14/4885LMNA 2173/4885SLC6A2 1255/4885 |
| US-20220340551-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | SI, CYP3A7, ERG28 | CYP2D6 14/4885LMNA 2173/4885SLC6A2 1255/4885 |
| US-20220213073-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | SI, CYP3A7, ERG28 | CYP2D6 14/4885LMNA 2173/4885SLC6A2 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.